VADALENTAMIG
UNII 5XEB9G6TR6
Substance Identification & Data
This profile provides standardized clinical and technical data for Vadalentamig, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 5XEB9G6TR6.
Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 3030203-93-8 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.
5XEB9G6TR6
3030203-93-8
N/A
Detailed Substance Profile
Preferred Name
VADALENTAMIG
Official standardized name for this substance within the FDA UNII nomenclature system.
INN ID
13892
Sequential identifier assigned via the WHO International Nonproprietary Name program.
Substance Type
Vadalentamig
ISO 11238 classification category (e.g., Chemical, Polymer, Protein).
Synonyms and Nomenclature
This section provides a complete list of nomenclature and identifier mappings for Vadalentamig. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.
FDA Official Name
Vadalentamig
Common Names & Synonyms
H-gamma1 heavy chain anti-KLRK1 Homo sapiens (H) (1-451) [VH (Homo sapiens IGHV3-21*01 (100%) -(IGHD) -IGHJ5*02 (100%), CDR-IMGT [8.8.15] (26-33.51-58.97-111)) (1-122) -Homo sapiens IGHG1*01, G1m17,1 CH1 K120, CH3 D12, L14, 14-G1v75 CH3 C5, 14-G1v90 CH3 E16, W88 (CH1 K120 (219) (123-220), hinge 1-15 (221-235), CH2 (236-345), CH3 Y5>C (354), D12 (361), L14 (363), K16>E (365), K88>W (414) (346-450), CHS K2>del (451)) (123-451)], (225-214')-disulfide with L-kappa light chain anti-KLRK1 Homo sapiens (L') (1'-214') [V-KAPPA (Homo sapiens IGKV1-12*01 (97.9%) -IGKJ4*01 (100%), CDR-IMGT [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (153'), V101 (191')) (108'-214')]; fused scFvkh-G1(h-CH2-CH3) heavy chain anti-EGFR Homo sapiens (H'') (1''-474'') [scFvkh anti-EGFR Homo sapiens (1''-246''), 11-scFv-v2 C120 (VL)-C49 (VH) [V-KAPPA (Homo sapiens IGKV1-33*01 (95.8%) -IGKJ1*01 (90.0%) Q120>C (100''), CDR-IMGT [6.3.9] (27''-32''.50''-52''.89''-97'')) (1''-107'') -20-mer tetrakis(tetraglycyl-seryl) linker (108''-127'') -VH (Homo sapiens IGHV4-61*01 (87.9%) -IGHD -IGHJ3*02 (100%), VH G49>C (173''), CDR-IMGT [10.7.11] (153''-162''.180''-186''.225''-235'')) (128''-246'') -2-mer glycyl-seryl linker (247''-248'') -Homo sapiens IGHG1*01, G1m17,1 CH3 D12, L14, 14-G1v91 CH3 R3, V84 .2, T85.1, 14-G1v74 CH3 C10 (hinge 6-15 (249''-258''), CH2 (259''-368''), CH3 Q3>R (375), S10>C (382''), D12 (384), L14 (386), D84.2>V (427), F85.1>T (433) (369''-473''), CHS K2>del (474'')) (249''-474'')]]; dimer (231-254'':234-257'':354-382'')-trisdisulfide, produced in a cell line of Chinese hamster ovary (CHO) cells, derived from the cell line CHO-K1, glycoform alfa
Immunoglobulin G1, bispecific, anti-(human epidermal growth factor receptor) (recombinant human monoclonal ABX-EGF single-chain variable fragment VL-peptide linker (synthetic 20-amino acid)-VH) fusion protein with immunoglobulin G1 (recombinant human γ1-chain hinge-CH2-CH3 fragment), (254→231′),(257→234′),(382→354′)-tris(disulfide) with immunoglobulin G1 [354-cysteine,365-glutamic acid,414-tryptophan,de-452-lysine] anti-(human/Macaca fascicularis killer cell lectin-like receptor KLRK1) (human monoclonal A49 γ1-chain) disulfide with human monoclonal A49 κ-chain
immunoglobulin (H-gamma1_L-kappa)_scFvkh-G1(h-CH2-CH3), anti-[Homo sapiens KLRK1 (killer cell lectin like receptor K1, NKG2D, KLR, NKG2-D, CD314)] and anti-[Homo sapiens EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB)], Homo sapiens monoclonal antibody, KLRK1 agonist, scFv derived from panitumumab, bispecific (vadalentamig)
vadalentamig [INN]
